Physician profile
Michael Soliman
NPI 1720518475
$1,414.42
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $653 · 2020: $193 · 2021: $328 · 2022: $110 · 2023: $102 · 2024: $28.02.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $130.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $130.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $279.90 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $243.66 | 2019-2021 | |
| Abbvie INC. | $178.40 | 2021-2024 | Duopa |
| Csl Behring | $123.45 | 2019 | |
| Strongbridge US INC. | $118.90 | 2019 | |
| Emd Serono, INC. | $111.49 | 2020-2021 | |
| Astrazeneca Pharmaceuticals Lp | $87.73 | 2023 | |
| Sk Life Science, INC. | $61.41 | 2021 | |
| Novartis Pharmaceuticals Corporation | $53.26 | 2019 | |
| Avanir Pharmaceuticals, INC. | $44.73 | 2019 | |
| Portola Pharmaceuticals, LLC | $37.68 | 2019-2020 | |
| Eisai INC. | $24.94 | 2020 | |
| Adamas Pharmaceuticals, INC. | $21.16 | 2019 | |
| Livanova USA, INC. | $15.66 | 2019 | |
| Ucb, INC. | $12.05 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Soliman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.